Abstract
Trans-rectal Ultrasound (TRUS) is a safe, cost-effective, radiation free imaging modality for evaluation of prostate. But unfortunately, hemospermia is known to be associated with TRUS -guided prostate biopsy. This study measured the incidence & risk factors, of hemospermia in patients undergoing trans-rectal ultrasonography (TRUS). A prospective observational study involving patients undergoing TRUS for suspected prostate cancer has been conducted at Al-Hussein and Sayed Galal, University Hospitals. 40patients were included in the study. The results showed that 18 out of 40 patients (45%) undergoing TRUS-guided prostatic biopsy, who were able to ejaculate, experienced hemospermia, which was associated with some degree of anxiety. The mean duration of hemospermia was 4 (+/- 1.4) weeks. The number of ejaculations before the complete resolution of hemospermia was 6 (+/- 5.6). None of the clinical and pathological factors were significant predictors of the duration of hemospermia.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
